Recently, Nanjing King-Friend Biochemical Pharmaceutical Co., LTD. (hereinafter referred to as "King-Friend") received an approval letter from the US Food and Drug Administration (hereinafter referred to as "FDA") for its Methylene Blue Injection, allowing it to be marketed and sold.

Methylene Blue Injection is indicated for the treatment of children and adult patients with acquired methemoglobinemia.

The approval of Methylene Blue Injection this time is a powerful proof that Jianyou's R&D strength and quality control are in line with international standards. This drug, which adheres to the strict standards of the FDA, will provide a new "life reducing agent" for patients with methemoglobinemia worldwide with its safe and effective therapeutic properties. From emergency rescue in the emergency room to precise intervention in daily diagnosis and treatment, Jianyou responds to the urgent global clinical demand for efficient treatment with high-quality international medication. Let every medication be a solemn commitment to life.